The ESMO Magnitude of Clinical Benefit Scale uses a rational, structured and consistent approach to derive a relative ranking of the magnitude of clinically meaningful benefit that can be expected from anti-cancer treatments.
The ESMO-MCBS v1.0 was launched in May 2015 and in September 2017 an updated version ESMO-MCBS v1.1 was launched. The forms and instructions for both versions can be found by selecting below:
The highest grade of the ESMO-MCBS is A in the curative setting and this is restricted to new curative treatments with a grade B also to be considered to trigger rapid reimbursement.
For non-curative indications 5 is the highest possible grade with 4 also to be considered to trigger rapid consideration for reimbursement.